The dry powder inhaler features of the Easyhaler that benefit the management of patients

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention, 2019. [cited 2020 Jan 20]. Available from: www.ginasthma.org
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. [cited 2020 Jan Available from: goldcopd.org
   Google Scholar
• Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir. 2011;J7:1308–1331.
   Google Scholar
• Lavorini F, Fontana GA, Usmani OS. New inhaler devices - the good, the bad and the ugly. Respiration. 2014;88:3–15.
   PubMed Web of Science ®Google Scholar
• Pepper A, Cooke A, Livingston L, et al. Asthma and chronic obstructive pulmonary disease inhalers: techniques for proper use. Allergy Asthma Proc. 2016;37:279–290.
   PubMed Web of Science ®Google Scholar
• Papi A, Ryan D, Soriano JB, et al. Relationship of inhaled corticosteroid adherence to asthma exacerbations in patients with moderate-to-severe asthma. J Allergy Clin Immunol Pract. 2018;6:1989–1998.
   PubMed Web of Science ®Google Scholar
• Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017; 5:1071–1081.
   PubMed Web of Science ®Google Scholar
• Al-Showair RA, Pearson SB, Chrystyn H. The potential of a 2Tone trainer to help patients use their metered-dose inhalers. Chest. 2007;131:1776–17s82.
   PubMed Web of Science ®Google Scholar
• Pleasant R, Hess D. Aerosol delivery devices for obstructive lung diseases. Respir Care. 2018;63:708–733.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Small M, Milligan G, et al. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108:358–365.
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med. 2011;105:1308–1315.
   PubMed Web of Science ®Google Scholar
• Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Resp Med. 2014;108:1195–1203.
   PubMed Web of Science ®Google Scholar
• Pitcairn G, Reader S, Pavia D, et al. Deposition of corticosteroid aerosol in the human lung by respimat soft mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18:264–272.
   PubMedGoogle Scholar
• Roche N, Dekhuijzen PN. The evolution of pressurized metered-dose inhalers from early to modern devices. J Aerosol Med Pulm Drug Deliv. 2016;29:311–327.
   PubMed Web of Science ®Google Scholar
• Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers–implications for in vitro testing. J Aerosol Med. 1993;6:99–110.
   PubMedGoogle Scholar
• Azouz W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J. 2012;21:208–213.
   PubMedGoogle Scholar
• Azouz W, Chetcuti P, Hosker HS, et al. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28:35–42.
   PubMed Web of Science ®Google Scholar
• Levy M, Carroll W, Izquierdo Alonso JL, et al. Understanding dry powder inhalers: key technical and patient preference attributes. Adv Ther. 2019 Sep 2;36:2547–2557.
   PubMed Web of Science ®Google Scholar
• Chodosh S, Flanders JS, Kesten S, et al. Effective delivery of particles with HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14:309–315.
   PubMedGoogle Scholar
• Chrystyn H. Closer to an ‘Ideal Inhaler’ with the Easyhaler®. Clin Drug Invest. 2006;26:175–183.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938.
   PubMed Web of Science ®Google Scholar
• van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2017;27:17001.
   PubMed Web of Science ®Google Scholar
• Sandler N, Holländer J, Långström D, et al. Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler). BMJ Open Respir Res. 2016;3:e000119.
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Everard ML, Haikarainen J, et al. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). J Aerosol Med Pulm Drug Deliv. 2014;27:329–340.
   PubMed Web of Science ®Google Scholar
• Nieminen MM, Vidgren M, Laurikainen K, et al. Easyhaler®, a novel multiple dose powder inhaler: clinically equivalent to salbutamol metered dose inhaler and easier to use. Respiration. 1994;61:37–41.
   PubMed Web of Science ®Google Scholar
• Haikarainen J, Rytila P, Roos S, et al. Dose uniformity of budesonide Easyhaler® under simulated real-life conditions and with low inspiration flow rates. Chron Respir Dis. 2018;15:265–271.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Safioti G, Keegstra JR, et al. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: an in-vitro comparison of Spiromax with Turbuhaler. Int J Pharm. 2015;491:268–276.
   PubMed Web of Science ®Google Scholar
• Abadelah M, Hazim F, Chrystyn H, et al. Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler. Eur J Pharm Sci. 2017;104:180–187.
   PubMed Web of Science ®Google Scholar
• Budesonide WO. + formoterol fumarate dihydrate for the treatment of asthma. Exp Opin Pharmacother. 2016;7:1023–1030.
   Google Scholar
• Lindberg A, Szalai Z, Pullerits T, et al. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology. 2007;12:732–739.
   PubMed Web of Science ®Google Scholar
• Lunborg M, Wille S, Bjermer L, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin. 2006;22:809–821.
   PubMed Web of Science ®Google Scholar
• Lahelma S, Sairanen U, Haikarainen J, et al. equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler. J Aerosol Med Pulm Drug Deliv. 2015;28:462–473.
   PubMed Web of Science ®Google Scholar
• Lahelma S, Vahteristo M, Metev H, et al. Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma. Resp Med. 2016;120:31e35.
   Web of Science ®Google Scholar
• Pirozynski D, Hantulik P, Almgren-Rachtan A, et al. Evaluation of the efficiency of single-inhaler combination therapy with budesonide/formoterol fumarate in patients with bronchial asthma in daily clinical practice. Adv Ther. 2017;34:2648–2660.
   PubMed Web of Science ®Google Scholar
• Tamasi L, Szilasi M, Galffy G. Clinical effectiveness of budesonide/formoterol fumarate Easyhaler for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes. Adv Ther. 2018;35:1140–1152.
   PubMed Web of Science ®Google Scholar
• Hantulik P, Wittig K, Henschel Y, et al. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany. Pneumonol Alergol Pol. 2015;83:365–377.
   PubMedGoogle Scholar
• Lavorini F, Ninane V, Haughney J, et al. Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Exp Opin Drug Deliv. 2013;10:1597–1602.
   PubMed Web of Science ®Google Scholar
• Syk J, Vinge I, Sörberg M, et al. A multicenter, observational, prospective study of the effectiveness of switching from budesonide/formoterol Turbuhaler® to budesonide/formoterol Easyhaler®. Adv Ther. 2019;36:1756–1769.
   PubMed Web of Science ®Google Scholar
• Price D, Thomas V, von Ziegenweidt J, et al. Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients. J Asthma Allergy. 2014;7:31–51.
   PubMedGoogle Scholar
• Braido F, Lavorini F, Blasi F, et al. Switching treatments in COPD: implications for costs and treatment adherence. Int J Chron Obstruct Pulmon Dis. 2015;10:2601–2608.
   PubMed Web of Science ®Google Scholar
• Thomas M, Price D, Chrystyn H, et al. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med. 2009;9:1.
   PubMedGoogle Scholar
• Müller V, Gálffy G, Orosz M, et al. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data. Int J Chron Obstruct Pulmon Dis. 2016;11:93.
   PubMed Web of Science ®Google Scholar